Immune cell drug activity testing provides comprehensive in vitro evaluation of the biological potency, cytotoxic function, and release characteristics of cellular immunotherapy products such as CAR-T, CAR-NK, TIL, and CIK cells. As a critical quality attribute required by global regulatory agencies, robust activity testing ensures product consistency, safety, and efficacy throughout development and manufacturing. This article outlines the sample types, testing items, analytical methods, and typical applications of professional immune cell drug activity testing.
Technical Overview
Immune cell drug activity testing refers to the systematic laboratory evaluation of the biological activity and functional potency of immune cell-based medicinal products. These products—including chimeric antigen receptor T cells (CAR-T), CAR-NK cells, TCR-engineered T cells, tumor-infiltrating lymphocytes (TILs), cytokine-induced killer (CIK) cells, and expanded natural killer (NK) cells—exert their therapeutic effects through target antigen recognition, direct cytotoxic killing, cytokine secretion, and sustained proliferation. Because these mechanisms of action cannot be confirmed by physicochemical analysis alone, functional activity testing is recognized as a core component of the quality control strategy for cell therapy products.
Biological potency is classified as a critical quality attribute under ICH Q6B, and analytical procedures must be validated in accordance with ICH Q2(R2) and relevant pharmacopeial biological assay chapters. Accredited third-party laboratories typically perform activity testing under quality management systems conforming to ISO/IEC 17025 and applicable national standards, providing scientifically defensible data for regulatory submissions, batch release, and product lifecycle management.
Testing Samples
CAR-T Cell Products
Engineered T cells expressing chimeric antigen receptors targeting tumor-associated antigens such as CD19, BCMA, CD22, and Claudin18.2. Activity testing evaluates antigen-specific cytotoxicity, cytokine release, CAR surface expression, and transduction efficiency from both fresh and cryopreserved final drug products.
CAR-NK and NK Cell Products
Primary or iPSC-derived natural killer cells, with or without chimeric antigen receptor modification. Functional assessment covers both CAR-mediated and innate killing pathways, activating receptor expression, and cytotoxic granule content.
TCR-Engineered T Cells and TILs
T cells engineered with tumor-specific T cell receptors or expanded tumor-infiltrating lymphocytes, requiring HLA-restricted antigen presentation assays to confirm specificity and peptide-dependent target cell lysis.
CIK Cells and Other Immune Cell Products
Cytokine-induced killer cells, gamma-delta T cells, dendritic cell-based vaccines, and other immune cell preparations. Testing confirms NKG2D-mediated cytotoxicity, co-stimulatory molecule expression, and activation status.
Starting Materials and Process Intermediates
Apheresis products, peripheral blood mononuclear cells (PBMCs), post-activation intermediates, and post-transduction harvests. Characterization of these materials supports process control, comparability studies, and investigation of manufacturing deviations.
Testing Items
Activity testing programs are tailored to the product's mechanism of action and typically incorporate the following functional endpoints:
- Target cell cytotoxicity and dose-dependent killing activity against antigen-positive and antigen-negative tumor cell lines
- Cytokine secretion profiles, including IFN-γ, IL-2, TNF-α, GM-CSF, and IL-6, following antigen stimulation
- Cell proliferation capacity and expansion kinetics upon repeated antigen challenge
- Surface phenotype characterization, including CD3, CD4, CD8, CD56, memory subsets, and activation markers
- CAR or TCR expression level and vector copy number-related transduction efficiency
- Degranulation marker (CD107a) mobilization and cytotoxic molecule expression (granzyme B, perforin)
- Exhaustion and differentiation markers such as PD-1, TIM-3, LAG-3, and TIGIT
- Antigen specificity confirmation using antigen-negative controls and irrelevant CAR controls
- Functional persistence and serial killing capability in long-term co-culture assays
Testing Methods
Flow Cytometry-Based Killing Assays
Effector cells are co-cultured with fluorescently labeled target cells at graded effector-to-target ratios. Viable target cell enumeration by flow cytometry enables precise quantification of specific lysis while allowing simultaneous assessment of effector cell phenotype and activation.
LDH Release and Calcein-AM Assays
Measurement of lactate dehydrogenase or fluorescent dye released from lysed target cells provides a label-free, high-throughput cytotoxicity readout suitable for screening and batch comparison. Chromium-51 release assays remain available as a classical reference method where required.
Luciferase Reporter and Live-Cell Imaging Assays
Luciferase-expressing target cells enable highly sensitive bioluminescent quantification of residual viable tumor cells. Real-time impedance-based and live-cell imaging platforms further resolve killing kinetics, providing rich data for potency assay development.
Cytokine Quantification
ELISA, ELISpot, and multiplex electrochemiluminescence platforms measure secreted cytokines and single-cell cytokine-producing frequencies following antigen restimulation, supporting both potency assessment and safety-related activity monitoring.
Proliferation and Expansion Assays
CFSE or CellTrace dye dilution combined with cell counting quantifies proliferative capacity and fold expansion, key indicators of in vivo persistence potential.
Method Validation and Data Integrity
Quantitative activity assays are validated for accuracy, precision, specificity, linearity, range, and robustness per ICH Q2(R2) and biological assay design principles, with relative potency calculated against qualified reference standards using parallel-line or four-parameter logistic models.
Applications
Immune cell drug activity testing supports the entire product lifecycle from early research through commercial supply:
- Potency assay development and qualification for IND-enabling CMC packages and clinical trial applications
- Batch release testing of clinical and commercial products against predefined acceptance criteria
- Stability studies evaluating activity retention during cryopreservation, storage, and transport
- Comparability testing following manufacturing process changes, scale-up, or technology transfer
- Screening of candidate constructs, culture conditions, and optimization of manufacturing parameters
- Investigation of out-of-specification results and support for regulatory responses
- Donor or starting material qualification for autologous and allogeneic products
FAQ
Why is biological activity testing required for immune cell drugs?
Regulatory agencies worldwide require demonstrated potency for all cell therapy products because biological activity directly reflects the mechanism of action and clinical efficacy. Activity data are essential for CMC documentation, lot consistency, and assurance that each manufactured batch functions as intended.
What is the preferred method for measuring cytotoxic activity?
No single method is universally mandated. Flow cytometry-based killing assays and luciferase reporter assays are widely adopted for their sensitivity and multiparametric capability, while LDH release offers simplicity for high-throughput screening. Method selection depends on product characteristics, target cells, and stage of development.
How should samples be submitted for activity testing?
Fresh cell products should be shipped under validated temperature-controlled conditions with defined time limits, while cryopreserved products must be transported in dry shippers or on dry ice with documented temperature monitoring. Accredited third-party laboratories provide specific shipping and chain-of-custody requirements.
How is an activity assay validated?
Validation follows ICH Q2(R2) principles adapted to biological assays, demonstrating specificity against relevant controls, dose-response linearity within the working range, intra- and inter-assay precision, and robustness to operational variables. Reference standards are qualified to enable relative potency reporting.
Can activity testing distinguish between antigen-specific and non-specific killing?
Yes. Well-designed assays incorporate antigen-negative target cells, irrelevant CAR controls, and HLA-mismatched or peptide-blocking conditions, allowing precise discrimination of antigen-specific activity from background or innate cytotoxicity.